Skip to content
Menu

Spyre Therapeutics, Inc. SYRE

Full chart Compare
Set alert

Price alert · SYRE

All alert types
93.47 USD -4.16 (-4.26%)

Regular-session close

93.47 0.00 0.00%

After hours · Nov 20, 4:52 PM ET

93.22 Day range 99.56
23.47 52-week range 109.00
YTD
+185.32%
1 year
+298.25%

5D -1.25 (-1.24%)

95100105FriMonTueWedThu99.52
Market cap
8.88B
EPS (ttm)
-2.49
Shares out
94.97M
Forward P/E
-25.31
YTD return
+185.32%
1-year return
+298.25%
50-day average
92.22
200-day average
77.98
Enterprise value
8.35B
Price / book
9.29
Volume
805.37K
Avg volume
1.27M
Open
95.93
Previous close
97.63
Day's range
93.22 – 99.56
52-week range
23.47 – 109.00
Beta
3.23
Analysts
Strong Buy
Price target
123.87 (+32.5%)
Earnings date
Feb 18, 2027

Key statistics

Free cash flow
-95.36M
Total cash
1.07B
Return on equity
-35.03%
Short % of float
13.02%

Fundamental scorecard

5 of 25 checks passed on SYRE’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SYRE Revenue — quarterly 0
SYRE Net income — quarterly -96.12M
SYRE EPS — quarterly -0.94

Earnings

SYRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 18, 2027Dec 30, 2026-1.01———
Nov 3, 2026Sep 30, 2026-0.82227-0.94-0.12-14.32%
Aug 4, 2026Jun 30, 2026-0.75885-0.36+0.40+52.56%
May 5, 2026Mar 31, 2026-0.66-0.74-0.08-12.12%
Feb 19, 2026Dec 31, 2025-0.66-0.70-0.04-6.06%
Nov 4, 2025Sep 30, 2025-0.76076-0.15+0.61+80.28%

Upgrades / downgrades

SYRE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026GuggenheimmainBuyBuy
Nov 4, 2026WedbushmainOutperformOutperform
Oct 19, 2026BTIGreitBuyBuy
Oct 12, 2026UBSinit—Buy
Oct 1, 2026JP Morganinit—Overweight
Oct 1, 2026BTIGreitBuyBuy

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
spyre.com

News

Your note

Sign in to keep a note on SYRE — it syncs with the Stock Master app.

Insider holders

SYRE insider holders
InsiderRelationLatest transactionDateShares held
ALBERS JEFFREY WDirectorConversion of Exercise of derivative securityAug 6, 20269,360
BURROWS SCOTT L.Chief Financial OfficerSaleSep 1, 202679,762
FAIRMOUNT FUNDS MANAGEMENT LLCUnknownConversion of Exercise of derivative securityJun 22, 20260
HENDERSON MICHAEL THOMASDirectorSaleJun 21, 202668,606
KING-JONES HEIDYOfficerConversion of Exercise of derivative securitySep 1, 20262,845
SLOAN SHELDONOfficerConversion of Exercise of derivative securityJun 30, 20260

Institution ownership

SYRE institution ownership
Holder% heldSharesValueReported
FMR, LLC14.21%13,496,5961.26BSep 29, 2026
Blackrock Inc.7.14%6,779,486633.68MSep 29, 2026
Paradigm Biocapital Advisors LP4.69%4,457,450416.64MSep 29, 2026
Vanguard Portfolio Management LLC4.28%4,063,789379.84MSep 29, 2026
Vanguard Capital Management LLC3.95%3,750,793350.59MSep 29, 2026
RTW Investments LP3.89%3,691,791345.07MSep 29, 2026

Fund ownership

SYRE fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.91%2,760,132257.99MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.61%2,482,298232.02MJun 29, 2026
SmallCap World Fund Inc2.37%2,247,758210.10MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.09%1,982,310185.29MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.79%1,699,846158.88MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund0.94%896,55983.80MJun 29, 2026